Share “Bristol-Myers enters three-year...”

Bristol-Myers enters three-year collaboration deal

Published on NewsOK Modified: February 12, 2013 at 7:19 am •  Published: February 12, 2013
Advertisement

NEW YORK (AP) — Bristol-Myers Squibb Co. will receive more than $480 million from a collaboration agreement with British consumer goods company Reckitt Benckiser Group PLC over the sale of several over-the-counter drugs mostly in Mexico and Brazil.

The New York drug developer said Tuesday Reckitt Benckiser will pay $438 million upfront for exclusive rights to sell products like the antacid Picot, the pain reliever Tempra and the cold-and-cough medicine Graneodin over three years. Reckitt Benckiser will buy the products from Bristol and pay royalties during the collaboration.

The British company also will pay an option fee of $44 million for the right to buy the products outright at the end of the three-year agreement. That includes acquiring sales and distribution rights, trademarks, inventories and other assets. The purchase price then will be based on average sales during a two-year period before the deal closes.

Bristol-Myers Squibb shares finished at $36.93 on Monday.


AROUND THE WEB

  1. 1
    Where does OU rank among college football's running back units?
  2. 2
    The best jobs for every personality type
  3. 3
    Lankford: Changing Washington 'takes strong families, strong churches and strong communities'
  4. 4
    Trial delayed for former sheriff's deputy charged with sexual battery
  5. 5
    County Commissioner booked on new charges; discussion on ouster set for Monday
+ show more

FEATURED JOBS



× Trending business Article